The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback